$STRW

Freedom Broker raises Strawberry Fields REIT price target on valuation

Freedom Broker raised its price target for Strawberry Fields REIT (NYSE:STRW) to $16.00 from $15.00 and kept a Buy rating. STRW last traded at $13.91, implying about 15% upside. The firm cited Q2 2026 adjusted funds from operations below expectations due to closing costs and higher interest expense, with limited capital activity and expected deal pickup in Q4 2026.

Original reporting
Published Aug 11, 2026, 3:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$STRW
Bullish
medium confidence
Mentioned
$STRW
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$STRWBullishLow
01

Why it matters

For STRW, the actionable element is the raised price target and the stated rationale: Q2 AFFO below expectations due to one-time financing closing costs and higher interest expense, with management expecting more deal activity in Q4 2026.

02

Market read

This is primarily a single-name valuation update with modest trading relevance, tied to expectations for future acquisitions.

03

What to watch

Deal activity is the key catalyst per the firm, but the article also notes capital activity was limited in the quarter, increasing execution/timing risk.

Relevance 5/10Novelty 5/10Timing: today’s analyst price-target update

Background

The piece frames a Freedom Broker valuation update for Strawberry Fields REIT alongside a brief market wrap about Hormuz jitters and CPI as the next macro catalyst.

Company-level read

Ticker impact

$STRWBullishMedium confidence
Context

Freedom Broker raised Strawberry Fields REIT’s price target to $16 from $15 and kept a Buy rating after Q2 AFFO missed expectations.

Expected impact

Near term, modest upside bias versus prior PT as traders price in the updated terminal multiple, but follow-through depends on Q4 acquisition activity.

Evidence & confidence

The article provides a concrete PT change and cites the specific Q2 variance drivers (one-time closing costs, higher interest expense) plus a stated expectation that deal activity picks up in Q4 2026.

Market effects

Signals continued investor focus on REIT valuation multiples (EV/EBITDA) and acquisition pipeline timing rather than immediate operating momentum.

None specified beyond general market jitters.

None specified.

Counterpoint

The PT increase may not change fundamentals if AFFO weakness persists and acquisition timing slips beyond Q4 2026.

Key entities

  • Strawberry Fields REIT

    Subject of the article; Freedom Broker raised its price target to $16 and maintained a Buy rating.

  • Freedom Broker

    Issued the price-target increase and valuation-multiple rationale.

Related articles

$STRWMed

Strawberry Fields REIT CEO Maps SNF Growth Strategy, 100% Rent Collection Record

Strawberry Fields REIT CEO highlighted growth strategy, 100% rent collection, and operator financial health. The company focuses on skilled nursing facilities, benefiting from aging demographics and regulatory barriers. It closed a $200M credit line, has low leverage, and trades at a discount to peers due to limited liquidity. The company generates $74M in AFFO, with a 10.5x AFFO valuation.

$STRWMed

Strawberry Fields REIT (STRW) Q2 2026 Earnings Call Transcript

Strawberry Fields REIT (STRW) held its Q2 2026 earnings call. For the first six months of 2026, revenue rose to $80 million (+6.4%) and net income was $18.4 million. AFFO was $73.9 million, with projected 10.1% AFFO growth per share in 2026. The company reported 100% rent collection, $300 million credit facility, and a $0.17 Q3 dividend.

$STRWMed

Strawberry Fields REIT Q2 Earnings Call Highlights

Strawberry Fields REIT (STRW) reported Q2 adjusted funds from operations (AFFO) of $73.9 million and projected 10.1% AFFO-per-share growth. It posted adjusted EBITDA of $135.7 million, 14.4% lease yield, and net debt to net assets of 49.8%. The board approved a $0.17 quarterly dividend. The company closed a $300 million credit facility and contracted to buy a Missouri hospital campus for $10.4 million.

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.